- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Triple class refractory/penta-refractory multiple myeloma (TCR/PR MM)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1636KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 207KB)
Selinexor – July 2021
Selinexor (TCR/PR MM): Tablet 20 mg; Xpovio®
Last updated
30 May 2025